Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;170(1):93-7.
doi: 10.1016/j.jsb.2009.12.011. Epub 2009 Dec 21.

Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase

Affiliations

Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase

Kathleen M Frey et al. J Struct Biol. 2010 Apr.

Abstract

Resistance to therapeutics such as trimethoprim-sulfamethoxazole has become an increasing problem in strains of methicillin-resistant Staphylococcus aureus (MRSA). Clinically isolated trimethoprim-resistant strains reveal a double mutation, H30N/F98Y, in dihydrofolate reductase (DHFR). In order to develop novel and effective therapeutics against these resistant strains, we evaluated a series of propargyl-linked antifolate lead compounds for inhibition of the mutant enzyme. For the propargyl-linked antifolates, the F98Y mutation generates minimal (between 1.2- and 6-fold) losses of affinity and the H30N mutation generates greater losses (between 2.4- and 48-fold). Conversely, trimethoprim affinity is largely diminished by the F98Y mutation (36-fold) and is not affected by the H30N mutation. In order to elucidate a mechanism of resistance, we determined a crystal structure of a complex of this double mutant with a lead propargyl-linked antifolate. This structure suggests a resistance mechanism consistent both for the propargyl-linked class of antifolates and for trimethoprim that is based on the loss of a conserved water-mediated hydrogen bond.

Keywords: antifolates; dihydrofolate reductase; methicillin-resistant Staphylococcus aureus; trimethoprim.

PubMed Disclaimer

Figures

Figure 1
Figure 1
a) 2 FoFc density (1.6 σ, gray) for compound 2 and residues Leu 5, Asp 27, Asn 30, Thr 111, and water molecule (red sphere), b) Omit 2 FoFc density (1.3 σ, blue) for compound 2 and residues Leu 5, Asp 27, Asn 30, Phe 92, Thr 111 and a water molecule (red sphere),c) compound 2 and the residues in the active site.
Figure 2
Figure 2
Residues in the active site that form hydrogen bonds to the diaminopyrimidine ring of compound 2 (lavender) for: (a) Sa (wt) DHFR (green) (PDB ID: 3FQ0); (b) Sa (F98Y) DHFR (cyan) (PDB ID: 3FQO); and (c) Sa (H30N, F98Y) DHFR (pink) (PDB ID: 3I8A). Water molecules are shown as colored spheres to match the enzyme. Interactions that are within hydrogen bonding distance are represented by dashed lines in black. Weakened hydrogen bonds are represented by dashed lined in red.

Similar articles

Cited by

References

    1. Archer GL, Coughter JP, Johnston JL. Plasmid-encoded trimethoprim resistance in staphylococci. Antimicrob Agents Chemother. 1986;29:733–740. - PMC - PubMed
    1. Beierlein JM, Frey KM, Bolstad DB, Pelphrey PM, Joska TM, Smith AE, Priestley ND, Wright DL, Anderson AC. Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase. J Med Chem. 2008;51:7532–7540. - PMC - PubMed
    1. Bhat TN, Cohen GH. OMITMAP: An electron density map suitable for the examination of errors in a macromolecular model. J Appl Cryst. 1984;17:244–248.
    1. Bolstad DB, Bolstad ES, Frey KM, Wright DL, Anderson AC. Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from Cryptosporidium. J Med Chem. 2008;51:6839–6852. - PMC - PubMed
    1. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–3108. - PubMed

Publication types

MeSH terms

LinkOut - more resources